Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Bone marrow transplant offers a potential cure for thalassemia by replacing the faulty blood-forming stem cells with healthy ...

Columnist Oluwatosin Adesoye, a doctor, sorts through the difference between sickle cell anemia and sickle cell disease — and ...